Literature DB >> 21654435

A health outcome assessment of the Cardio Metabolic Mission Health Program at Novartis.

Edward Mauceri1, Catherine Bienkowski, Kristin A Hanson, Joseph J Doyle, James Jackson, Susan Bramer.   

Abstract

OBJECTIVE: To assess the impact of the Novartis Cardio Metabolic Program--an education, awareness, and health management initiative--on hypertension, hyperlipidemia, diabetes mellitus, and obesity within the Novartis employee population.
METHODS: A prospective, 6-month pre-/post assessment to determine improvement in blood pressure (BP) control and risk factors after implementation of Novartis Cardio Metabolic.
RESULTS: A total of 238 subjects with cardiovascular risk factors participated. In the hypertension cohort, overall BP control improved from 38% at baseline to 79% at follow-up (P < 0.0001). In the hyperlipidemia cohort, low-density lipoprotein cholesterol control improved significantly between baseline and study end (22% to 34%, P = 0.0004). In the diabetes mellitus cohort, the rate of glycosylated hemoglobin control increased from 83.7% to 86.2% (P = 0.69). There was a significant decrease in body mass index at follow-up (P < 0.0001).
CONCLUSION: Novartis Cardio Metabolic educational and health interventions helped to improve health awareness among Novartis employees.

Entities:  

Mesh:

Year:  2011        PMID: 21654435     DOI: 10.1097/JOM.0b013e31821b7ade

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Thinking inside the box: the health cube paradigm for health and wellness program evaluation and design.

Authors:  Robert Goldsmith; Sharon Harris
Journal:  Popul Health Manag       Date:  2013-07-20       Impact factor: 2.459

Review 2.  Strategies for Worksite Health Interventions to Employees with Elevated Risk of Chronic Diseases.

Authors:  Lu Meng; Marilyn B Wolff; Kelly A Mattick; David M DeJoy; Mark G Wilson; Matthew Lee Smith
Journal:  Saf Health Work       Date:  2016-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.